Rocha Lima C M, Urbanic J J, Lal A, Kneuper-Hall R, Brunson C Y, Green M R
H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.
Semin Oncol. 2001 Jun;28(3 Suppl 10):34-43. doi: 10.1053/sonc.2001.22534.
Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress. Semin Oncol 28 (suppl 10):34-43.
包括吉西他滨和伊立替康（健择；礼来公司，印第安纳波利斯，印第安纳州）在内的非铂类联合方案已开始出现，用于治疗多种恶性肿瘤。吉西他滨和伊立替康是耐受性良好的单一药物，各自具有广泛的抗肿瘤活性。临床前数据表明，这两种药物联合使用时具有协同作用。一项I期试验确定了一种耐受性良好的联合方案，每3周在第1天和第8天使用这两种药物。II期数据表明该联合方案对胰腺癌有活性，一项比较两药联合方案与单独使用吉西他滨的III期试验正在既往未接受治疗的胰腺癌患者中进行。其他评估该联合方案对多种其他肿瘤（如非小细胞肺癌、小细胞肺癌、乳腺癌、结直肠癌和非霍奇金淋巴瘤）影响的II期试验即将开展或正在进行中。《肿瘤学 Seminars》28（增刊10）：34 - 43。
